Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and Its Open-Label Extension Up to 1 Year
Authors: Laura C. Coates, Robert B.M. Landewé, Iain Mcinnes, Philip J. Mease, Christopher T. Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Alice B Gottlieb, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola
